Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Detection of genes from five gene expression panels (GEPs) in breast tumor samples using NanoString nCounter analysis

ABSTRACT: The aim of this study was to examine the effect of intra-tumor heterogeneity (ITH) on detection of genes within gene expression panels (GEPs), and the subsequent ability to predict prognostic risk. Multiplexed barcoded RNA analysis was used to measure the expression of 141 genes from five GEPs (Oncotype Dx, MammaPrint, PAM50, EndoPredict, and BCI) in breast cancer tissue sections and tumor-rich cores from 71 ER positive node-negative tumors. Tumor regions with high Ki67 and/or low PR were also used to punch cores, potentially representing aggressive areas of a tumor. In addition to examining the effect of ITH on measurement of GEPs, the effect of ITH on prediction of prognosis in the Oncotype Dx assay was also assessed.

ORGANISM(S): Homo sapiens

PROVIDER: GSE79378 | GEO | 2017/02/08

SECONDARY ACCESSION(S): PRJNA315657

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

NanoString nCounter NF1-mutant melanoma gene expression

Project description:Purpose: Digital spatial profiling was used to elucidate the interplay between the tumor cells and the surrounding microenvironment FFPE tissues. Methods: Two tissue microarrays (TMA) were generated from each FFPE block using the ISNET Galileo CK4500 computer-driven tissue microarray. Images of H&E-stained cores were demarcated by a pathologist and were utilized alongside NanoString immunofluorescent staining for morphology markers S100, CD45, CD3, and DAPI to draw region of interest.

2022-04-16 | GSE200904 | GEO

Gene expression analysis of CALGB 9741 patient tumor samples using the nCounter RUO-PAM50 signature

Project description:Intrinsic subtyping of breast cancer was performed using an nCounter RUO-PAM50 gene expression assay to determine the ability of instrinsic subtyping to predict what patients may benefit from altered chemotherapy scheduling in the CALGB 9741 clinical trial population. FFPE primary breast tumor samples archived at the CALGB Pathology Coordinating Office (PCO) were used to obtain total RNA for instrinsic subtyping using the nCounter Analysis System. Gene-expression profiles were generated for 1321 of 1471 patient samples (90%) suitable for inclusion in this study.

2015-11-10 | E-GEOD-74821 | biostudies-arrayexpress

Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer (CGH)

Project description:The aim of this study was to investigate the effect of VEGF targeted therapy (sunitinib) on intratumoral heterogeneity (ITH) in metastatic clear cell renal cancer (mRCC). To explore ITH in detail, multiple tumor samples were taken from the primary renal tumors of mRCC patients who were sunitinib treated (n=23) or untreated (n=23). ITH of pathological grade, DNA (using array-based comparative genomic hybridisation), RNA (Illumina Beadarray) and protein (reverse phase protein array) were evaluated. Tumor grade heterogeneity was greater in treated compared to untreated tumors (P=0.002). Unsupervised and supervised analysis, for renal cancer driver, hypoxia and stromal gene signatures, was then performed. In untreated patient tumor samples, significant ITH occurred in chromosomal aberrations, RNA and protein expression, with clustering of DNA and RNA correlating for individual patients. In unsupervised analysis sunitinib therapy was not associated with increased ITH in DNA or RNA. However there was an increase in ITH for the driver mutation and hypoxia gene signatures (DNA and RNA) as well as increasing variability of protein expression with treatment (p<0.05). Despite this variability, significant chromosomal and RNA changes to targets of sunitinib, such as VHL, PBRM1 and CAIX, occurred in the treated samples. Together these findings suggest that sunitinib treatment has significant effects on the expression and ITH of key tumor and treatment specific genes. The results do not support the hypothesis that resistant clones are selected and predominate after initiation of targeted therapy; instead it appears that an initial clonal diversification occurs, supporting the hypothesis of polyclonal drug resistance. 128 samples from patients with clear cell renal cell carcinoma, including biological replicates of nephrectomy samples. Source of samples includes both biopsy and nephrectomy. DNA extracted from FFPE and fresh frozen tissue samples.

2015-05-25 | E-GEOD-67818 | biostudies-arrayexpress

CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors post-chemotherapy

2014-02-04 | GSE46275 | GEO

CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors post-chemotherapy

Project description:Analysis of MCA205 tumors developed in C57bl/6 mice on day 2, 7 and 10 after intratumoral treatment with doxorubicin (DX) or PBS solvent. DX triggers the immunogenicity of dying tumor cell and activates anti-tumor immunity. Results provided insight into molecular basis of DX induced immune response. C57bl/6 mice bearing palpable MCA205 fibrosarcoma tumors (25-45mm2) were treated with DX or PBS intratumorally and tumors were recovered 2, 7 or 10 days post treatment. DX treated samples on day 7 were also divided into responder and non responder groups according to tumor shrinkage.

2014-02-04 | E-GEOD-46275 | biostudies-arrayexpress

Beneficial effects of physical exercise and an orally active mGluR2/3 antagonist pro-drug on neurogenesis and behavior in an Alzheimer’s amyloidosis model

Project description:BCI-838 is a pro-drug whose active metabolite BCI-632 is an antagonist at the group II metabotropic glutamate receptor (mGluR2/3). Hippocampal dentate gyrus of four-month old mouse model of AD amyloid pathology (APP/PS1) were investigated via transcriptomics analysis following BCI-838 treatment and physical exercise. Findings demonstrate up-regulated brain-derived neurotrophic factor (BDNF), PIK3C2A of the PI3K-MTOR pathway, and metabotropic glutamate receptors, and down-regulated EIF5A of ketamine-modulating mTOR activity. Our study points to BCI-838 as a safe and orally active compound capable of mimicking the beneficial effect of exercise on AHN, learning behavior, and anxiety in a mouse model of AD neuropathology.

2022-05-25 | GSE203554 | GEO

Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer (CGH)

2015-05-25 | GSE67818 | GEO

Gene expression analysis of CALGB 9741 patient tumor samples using the nCounter RUO-PAM50 signature

2015-11-10 | GSE74821 | GEO

Expression profiling by high throughput sequencing to evaluate the effect of aroylated phenylenediamine HO53 on autophagy induction in mature human bronchial epithelial cells (BCi-NS1.1 cell line)

Project description:We used RNA sequencing to exploit molecular mechanisms behind HO53 induced autophagy in mature human bronchial epithelial cells (BCi-NS1.1 cell line). We performed transcriptome analysis of mature bronchial epithelial cells (BCi-NS1.1 cell line) treated with aroylated phenylenediamine HO53 for different time points 4 h, 8 h and 24 h and compared it to transcriptome of untreated cells collected at the same time points. A broad effect of HO53 on the gene expression in mature human lung epithelial cells (BCi-NS1.1) shows molecular signature for pathways involved in autophagy regulation. The expression pattern for selected genes was reconfirmed by qRT-PCR using SYBR Green reagent.

2023-10-30 | GSE160542 | GEO

Transcriptome-wide gene expression analysis of prostate cancer (PCa) needle biopsies

Project description:We assessed transcriptome-wide gene expression in needle biopsies of PCa patients prior to radical prostatectomy (RP) by next-generation sequencing (HiSeq 2500). We applied Cox proportional hazard models to the cohorts from different platforms and specimen types and combined the evidence from these by fixed effect meta-analysis to identify genes predictive for time to DoD (death of disease). Genes were combined by a weighted median approach into a prognostic score. Tumor cell content and GS from the biopsy cores were evaluated by pathologists. If applicable, the hospital provided tissue sections from the biopsy with the highest tumor cell content. If multiple biopsy cores were used for analysis, the average tumor cell content of all the samplings (typically 2 o 3 cores) was calculated. The primary clinical endpoint of the cohort was death of disease (DoD).

2020-07-21 | GSE134171 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data